Moderna and Merck: mRNA vaccine prevents melanoma recurrence in high-risk patients

Moderna and Merck announced that their experimental mRNA vaccine successfully prevented the return and spread of melanoma in high-risk patients. The results have been described as a significant breakthrough that could accelerate the drug's regulatory approval. The findings represent a potentially major advance in cancer treatment.